Sugi Predict

Sugi Predict / Compounds / SCHEMBL3388749

SCHEMBL3388749

SCHEMBL3388749

CCOC(=O)[C@H]1NCCC1O

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 4/20 0.39
▸ PPM1B O75688 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PPP1CC P36873 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ AGL P35573 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8427865 1.00 SPHK1 (0.39) SPHK1PPM1BPTPN1PPP1CCMAPT
SCHEMBL19973666 1.00 SPHK1 (0.39) SPHK1PPM1BPTPN1PPP1CCMAPT
SCHEMBL116264 1.00 SPHK1 (0.39) SPHK1PPM1BPTPN1PPP1CCMAPT
SCHEMBL6846988 1.00 SPHK1 (0.39) SPHK1PPM1BPTPN1PPP1CCMAPT
Hydrochloric Acid SCHEMBL4489520 0.98 SPHK1 (0.38) SPHK1PPM1BPTPN1PPP1CCMAPT
Hydrochloric Acid SCHEMBL953016 0.98 SPHK1 (0.38) SPHK1PPM1BPTPN1PPP1CCMAPT
Hydrochloric Acid SCHEMBL5578417 0.98 SPHK1 (0.38) SPHK1PPM1BPTPN1PPP1CCMAPT
SCHEMBL15955679 0.83 SPHK1 (0.44) SPHK1TSHR
SCHEMBL23555977 0.82 ALDH1A1 (0.40) PPM1BPTPN1PPP1CCMAPT
SCHEMBL24524725 0.82 ALDH1A1 (0.40) PPM1BPTPN1PPP1CCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737819-B1 AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE DSM IP ASSETS BV (NL) 2010-12-22 — — EP claimed
US-20100099727-A1 Amino acid and peptide conjugates of arylalkylic acids for cosmetic use DSM IP ASSETS B.V. (NL) 2010-04-22 — — US claimed
US-20080234344-A1 Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use DSM IP ASSETS B.V. (NL) 2008-09-25 — — US claimed
US-20080176923-A1 Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors SALAMA ZOSER B 2008-07-24 — — US claimed
US-20070021330-A1 Aza-peptide macrocyclic hepatitis c serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-01-25 — — US claimed
EP-1737819-A1 AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE DSMIP Assets B.V. (NL) 2007-01-03 — — EP claimed
US-7125845-B2 Aza-peptide macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2006-10-24 — — US claimed
EP-1711462-A1 PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS Salama, Zoser B. nat.rer.Dr. (DE) 2006-10-18 — — EP claimed
WO-2005092850-A1 AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE DSM IP ASSETS B.V. (NL) 2005-10-06 — — WO claimed
WO-2005058816-A1 PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS SALAMA ZOSER B (DE) 2005-06-30 — — WO claimed
US-20050065073-A1 Aza-peptide macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2005-03-24 — — US claimed
WO-2005010029-A1 AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2005-02-03 — — WO claimed
US-20250295157-A1 METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2025-09-25 — — US disclosed
US-12349713-B2 Methods for the improvement and maintenance of weight loss SOCIETE DES PRODUITS NESTLE S.A. (CH) 2025-07-08 — — US disclosed
EP-4099849-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE Société des Produits Nestlé S.A. (CH) 2022-12-14 — — EP disclosed
US-20220369685-A1 COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE NESTLE SA (CH) 2022-11-24 — — US disclosed
WO-1992018155-A1 BRADYKININ TYPE PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
WO-1992018155-A1 BRADYKININ TYPE PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234344-A1 Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use NGLY1, HRH4, C3AR1 SPHK1 3811/4885PPM1B 4000/4885PTPN1 3128/4885
US-20070021330-A1 Aza-peptide macrocyclic hepatitis c serine protease inhibitors VIP, CTSC, DPP4 SPHK1 1169/4885PPM1B 508/4885PTPN1 200/4885
US-20100099727-A1 Amino acid and peptide conjugates of arylalkylic acids for cosmetic use NGLY1, HRH4, C3AR1 SPHK1 3811/4885PPM1B 4000/4885PTPN1 3128/4885
US-20050065073-A1 Aza-peptide macrocyclic hepatitis C serine protease inhibitors VIP, CTSC, PRSS1 SPHK1 1240/4885PPM1B 499/4885PTPN1 179/4885
US-20080176923-A1 Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors PREP, PRAP1, VHL SPHK1 1193/4885PPM1B 707/4885PTPN1 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.